Institute for Wealth Management LLC. lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 2,426 shares of the life sciences company’s stock after purchasing an additional 42 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Illumina were worth $898,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Carroll Financial Associates Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at approximately $32,000. Creative Financial Designs Inc. ADV acquired a new position in Illumina during the 2nd quarter worth approximately $36,000. Valeo Financial Advisors LLC boosted its position in Illumina by 49.2% during the 2nd quarter. Valeo Financial Advisors LLC now owns 97 shares of the life sciences company’s stock worth $36,000 after acquiring an additional 32 shares during the last quarter. Bainco International Investors acquired a new position in Illumina during the 1st quarter worth approximately $33,000. Finally, Capital Square LLC acquired a new position in Illumina during the 1st quarter worth approximately $36,000. Institutional investors and hedge funds own 89.86% of the company’s stock.
ILMN traded down $0.62 during trading hours on Friday, reaching $382.16. The company’s stock had a trading volume of 933,505 shares, compared to its average volume of 773,438. Illumina, Inc. has a 52 week low of $196.78 and a 52 week high of $402.14. The company’s 50-day moving average is $370.94 and its 200-day moving average is $319.27. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.74 and a current ratio of 4.10. The firm has a market cap of $56.18 billion, a PE ratio of 60.18, a price-to-earnings-growth ratio of 5.65 and a beta of 1.00.
A number of research firms have weighed in on ILMN. Piper Sandler reduced their price target on Illumina from $370.00 to $356.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. BidaskClub raised Illumina from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Robert W. Baird downgraded Illumina from an “outperform” rating to a “neutral” rating and set a $310.00 price target for the company. in a research report on Tuesday, April 21st. Cowen upped their price objective on Illumina from $275.00 to $320.00 and gave the stock an “outperform” rating in a research note on Friday, May 1st. Finally, Guggenheim cut Illumina from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 7th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $343.20.
In related news, SVP Susan H. Tousi sold 600 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $325.00, for a total value of $195,000.00. Following the sale, the senior vice president now owns 48,054 shares in the company, valued at approximately $15,617,550. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Susan H. Tousi sold 300 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $350.00, for a total value of $105,000.00. Following the completion of the transaction, the senior vice president now directly owns 47,754 shares in the company, valued at $16,713,900. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,707 shares of company stock worth $10,819,532. 0.38% of the stock is owned by company insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.